The Food and Drug Administration has approved dozens of drugs for new hematology/oncology indications this year. Host David Henry, MD, was joined by David Mintzer, MD, and other colleagues at Penn Medicine in Philadelphia – Justine Cohen, DO, and Ingrid Kohut, DO – to discuss some of these approvals. Dr. Mintzer reviewed: The "game-changing" approval of niraparib (Zejula) in advanced ovarian, fallopian tube, or primary peritoneal cancer. The "exciting" approval of sacituzumab govitecan-hziy (Trodelvy) in metastatic triple-negative breast cancer. The "COVID-relevant" approval of a new dosing regimen for pembrolizumab (Keytruda) – 400 mg every 6 weeks – across all approved adult indications. The "niche" approval of mitomycin (Jelmyto) for adults with low-grade upper tract urothelial cancer. And several other approvals the FDA granted this year. Details on all approvals are available on the FDA website. * * * Disclosures: Dr. Henry and all guests reported having no relevant disclosures. * * * For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: [email protected] Interact with us on Twitter: @MDedgehemonc David Henry on Twitter: @davidhenrymd

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related